Last $13.84 USD
Change Today +0.1995 / 1.46%
Volume 5.8K
DPRX On Other Exchanges
As of 1:04 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

dipexium pharmaceuticals inc (DPRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/13/14 - $15.86
52 Week Low
05/15/14 - $8.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

dipexium pharmaceuticals inc (DPRX) Related Businessweek News

No Related Businessweek News Found

dipexium pharmaceuticals inc (DPRX) Details

Dipexium Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibiotics for the treatment of infectious diseases. It develops Locilex (pexiganan cream 0.8%), a novel, broad spectrum, and topical antibiotic, which is in phase 3 clinical trials for the treatment of mild infections of diabetic foot ulcers. The company was founded in 2010 and is based in New York, New York.

2 Employees
Last Reported Date: 03/13/14
Founded in 2010

dipexium pharmaceuticals inc (DPRX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $219.3K
Co-Founder, Executive Chairman and Managing P...
Total Annual Compensation: $219.3K
Compensation as of Fiscal Year 2013.

dipexium pharmaceuticals inc (DPRX) Key Developments

Dipexium Pharmaceuticals Announces Completion and Initial Results of Phase 1 Skin Sensitization Trial of Locilex®

Dipexium Pharmaceuticals, Inc. announced completion and initial results of DPX-120, a Phase 1 skin sensitization trial of Locilex® (pexiganan cream 0.8%), the Company's novel, broad-spectrum topical antibiotic peptide. DPX-120 was a single-center, double-blind study in healthy adult subjects with the primary objective of evaluating the potential of Locilex® and its vehicle cream to induce contact sensitization by repetitive application to human skin. Volunteers received applications of Locilex®, vehicle cream, and a low irritant control 3 times each week for 3 weeks during an induction phase, followed by 2 weeks without dosing and then a single challenge dose to intact skin. Visual skin irritation assessments were performed by trained and blinded evaluators using a well-established, FDA-recognized standardized rating scale. In total, 203 evaluable healthy adult subjects were assessed for contact sensitization. The low irritant control showed no contact sensitization as expected, indicating a successful trial. Vehicle cream also showed no induction of contact sensitization. Locilex demonstrated low potential for inducing contact sensitization. In total, only three out of 203 evaluable subjects were characterized as sensitized, which was better than anticipated by the Company and its scientific consultants based upon published studies conducted with other topical antibiotics.

Dipexium Pharmaceuticals, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 through Feb-10-2015

Dipexium Pharmaceuticals, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 through Feb-10-2015. Venue: The Waldorf Astoria, New York, New York, United States. Presentation Date & Speakers: Feb-09-2015, David P. Luci, Co-Founder, Chief Executive Officer, President, Managing Partner, Principal Financial Officer, Principal Accounting Officer, Secretary and Director.

Dipexium Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Dipexium Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DPRX:US $13.84 USD +0.1995

DPRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DPRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation DPRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIPEXIUM PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at